247 related articles for article (PubMed ID: 21784045)
1. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening.
Wilschut JA; Hol L; Dekker E; Jansen JB; Van Leerdam ME; Lansdorp-Vogelaar I; Kuipers EJ; Habbema JD; Van Ballegooijen M
Gastroenterology; 2011 Nov; 141(5):1648-55.e1. PubMed ID: 21784045
[TBL] [Abstract][Full Text] [Related]
2. Fecal occult blood testing when colonoscopy capacity is limited.
Wilschut JA; Habbema JD; van Leerdam ME; Hol L; Lansdorp-Vogelaar I; Kuipers EJ; van Ballegooijen M
J Natl Cancer Inst; 2011 Dec; 103(23):1741-51. PubMed ID: 22076285
[TBL] [Abstract][Full Text] [Related]
3. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness and projected national impact of colorectal cancer screening in France.
Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
7. Screening based on risk for colorectal cancer is the most cost-effective approach.
Dan YY; Chuah BY; Koh DC; Yeoh KG
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):266-71.e1-6. PubMed ID: 22100624
[TBL] [Abstract][Full Text] [Related]
8. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
[TBL] [Abstract][Full Text] [Related]
13. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
[TBL] [Abstract][Full Text] [Related]
14. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
[TBL] [Abstract][Full Text] [Related]
15. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening.
Berchi C; Guittet L; Bouvier V; Launoy G
Int J Technol Assess Health Care; 2010 Jan; 26(1):48-53. PubMed ID: 20059780
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening.
Goede SL; van Roon AH; Reijerink JC; van Vuuren AJ; Lansdorp-Vogelaar I; Habbema JD; Kuipers EJ; van Leerdam ME; van Ballegooijen M
Gut; 2013 May; 62(5):727-34. PubMed ID: 22490518
[TBL] [Abstract][Full Text] [Related]
18. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
Haug U; Hundt S; Brenner H
Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
[TBL] [Abstract][Full Text] [Related]
19. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
